Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark E Cooper

Showing results (11-20 of 399) with videos related to

Pageof 40
Sort By:
Nature Reviews. Nephrology|September 10, 2014
Diabetic nephropathy: renoprotective effects of pentoxifylline in the PREDIAN trialTony He, Mark E Cooper
Journal of Diabetes Investigation|May 21, 2014
Pathogenesis of diabetic nephropathyZemin Cao, Mark E Cooper
Kidney International|January 5, 2024
YB-1: the Jekyll and Hyde of kidney disease?Phillip Kantharidis, Mark E Cooper
Nature Clinical Practice. Endocrinology & Metabolism|February 5, 2009
Does intensive glycemic control for type 2 diabetes mellitus have long-term benefits for cardiovascular disease risk?Georgia Soldatos, Mark E Cooper
Acta Diabetologica|September 28, 2011
Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetesZemin Cao, Mark E Cooper
Circulation. Cardiovascular Imaging|March 11, 2016
Glycemic Control and Heart Failure: Separating the Contributors to Left Ventricular DysfunctionThomas H Marwick, Mark E Cooper
Journal of Hypertension|August 27, 2002
Turning up the heat: heat shock proteins, hypertension and cardiovascular riskMerlin C Thomas, Mark E Cooper
Kidney International Reports|September 13, 2021
The Discordance Between the Renal Histopathology and Clinical Presentation of Diabetic Nephropathy Calls for Novel Approaches for the Prediction and Monitoring of Kidney Failure in DiabetesJakob A Østergaard, Mark E Cooper
Kidney International Reports|December 19, 2022
Treatment of Type 2 Diabetes With <i>GLP-1</i> Receptor Agonists Among Patients With CKDJakob A Østergaard, Mark E Cooper
Lancet (London, England)|November 9, 2010
Into the light? Diabetic nephropathy and vitamin DMerlin C Thomas, Mark E Cooper
Pageof 40

Showing results (11-20 of 399) with videos related to

Sort By:
Pageof 40
Nature Reviews. Nephrology|September 10, 2014
Diabetic nephropathy: renoprotective effects of pentoxifylline in the PREDIAN trialTony He, Mark E Cooper
Journal of Diabetes Investigation|May 21, 2014
Pathogenesis of diabetic nephropathyZemin Cao, Mark E Cooper
Kidney International|January 5, 2024
YB-1: the Jekyll and Hyde of kidney disease?Phillip Kantharidis, Mark E Cooper
Nature Clinical Practice. Endocrinology & Metabolism|February 5, 2009
Does intensive glycemic control for type 2 diabetes mellitus have long-term benefits for cardiovascular disease risk?Georgia Soldatos, Mark E Cooper
Acta Diabetologica|September 28, 2011
Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetesZemin Cao, Mark E Cooper
Circulation. Cardiovascular Imaging|March 11, 2016
Glycemic Control and Heart Failure: Separating the Contributors to Left Ventricular DysfunctionThomas H Marwick, Mark E Cooper
Journal of Hypertension|August 27, 2002
Turning up the heat: heat shock proteins, hypertension and cardiovascular riskMerlin C Thomas, Mark E Cooper
Kidney International Reports|September 13, 2021
The Discordance Between the Renal Histopathology and Clinical Presentation of Diabetic Nephropathy Calls for Novel Approaches for the Prediction and Monitoring of Kidney Failure in DiabetesJakob A Østergaard, Mark E Cooper
Kidney International Reports|December 19, 2022
Treatment of Type 2 Diabetes With <i>GLP-1</i> Receptor Agonists Among Patients With CKDJakob A Østergaard, Mark E Cooper
Lancet (London, England)|November 9, 2010
Into the light? Diabetic nephropathy and vitamin DMerlin C Thomas, Mark E Cooper
Pageof 40